Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar;10(3):1308-1313.
doi: 10.21037/jtd.2018.03.43.

Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction

Elaine M Walsh  1 , Ronan J Kelly  1
Affiliations
Editorial

Single agent anti PD-1 inhibitors in esophageal cancer-a first step in a new therapeutic direction

Elaine M Walsh et al. J Thorac Dis. 2018 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. R. Kelly has received research funding from BMS, Astrazeneca and Eli Lilly. Dr. R. Kelly is an advisory board member for BMS, Eli Lilly, Astellas, GritStone Oncology, EMD Serono, Novartis. Dr. E. Walsh has no conflicts of interest to declare.

Comment in

Comment on

References

    1. Fuchs CS, Doi T, Jang RW, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 2017;35:abstr 4003.
    1. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-71. 10.1016/S0140-6736(17)31827-5 - DOI - PubMed
    1. Ohtsu A, Tabernero J, Bang YJ, et al. Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study. J Clin Oncol. 2016 doi: 10.1200/jco.2016.34.4_suppl.tps183. [Epub ahead of print] - DOI
    1. Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma [press release]. Available online: http://investors.merck.com/news/press-release-details/2017/Merck-Provide...
    1. Bang YJ, Wyrwicz L, Park YI, et al. Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial. J Clin Oncol 2016. [Epub ahead of print].

LinkOut - more resources